Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OVO Joint is a multi-ingredient nutraceutical supplement developed by Medcell Pharma for the comprehensive management of joint health, specifically targeting osteoarthritis and osteopenia. The formulation is a synergistic combination of four patented or standardized ingredients: Ovomet (eggshell membrane-derived collagen hydrolysate), Myrliq (Commiphora myrrha extract), ch-OSA (choline-stabilized orthosilicic acid), and sodium hyaluronate. These components are designed to reduce joint pain and inflammation while supporting the structural integrity of cartilage and bone density. Marketed as a specialty nutritional product rather than a pharmaceutical drug, OVO Joint represents a collaboration between Medcell Pharma and international partners Eggnovo (Spain), Biosfered (Italy), and BioMinerals (Belgium).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on OVO Joint.